Hamlet BioPharma Secures New Patents and Funding
Hamlet BioPharma has announced the granting of new patents in Japan and India, alongside securing approximately 8.5 million SEK in funding through warrant exercises.
Pharmaceutical company Hamlet BioPharma announced on May 18, 2026, that it has received new patents and patent allowances in Japan and India. This expands the company's intellectual property portfolio for its cancer and infection therapy development.
Earlier in March 2026, Hamlet BioPharma successfully raised approximately 8.5 million SEK (around 800,000 EUR) through the exercise of its TO5B series warrants. The company stated this capital infusion provides significant support for its ongoing operations and development activities.
Hamlet BioPharma has maintained regular communication with investors, including monthly meetings and financial reporting. A notable event in May 2026 was an investor meeting held in conjunction with the release of the company's Q3 interim report.
The company's core research involves valdkemalin, an alpha-vinca derivative being investigated for its potential in treating inflammatory conditions and cancer cells. Hamlet BioPharma has previously secured patent protection in the United States, Europe, and China.